A phase I pilot study of BCNU plus thymidine in patients with refractory cancer

Cancer Investigation

Volumn 14, Issue 3, 1996, Pages 218-224

  Schultz, Michelle Z ^a   Sandler, Alan B ^a   Durivage, Henry J ^a   Cooper, Dennis L ^a,b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; THYMIDINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER; CANCER RECURRENCE; CLINICAL TRIAL; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0029766885     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909609012142     Document Type: Article

References (39)

1. Poon MA, O'Connell MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407-1418, 1989.
2. Erlichman C, Fine S, Wong A, et al: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6:469-475, 1988.
3. Wadler S, Schwartz EL, Goldman M, et al: Fluorouracil and recombinant alfa-2a-interferon: An active regimen against advanced colorectal carcinoma. J Clin Oncol 7:1769-1775, 1989.
4. Grem JL, Chu E, Boarman D, et al: Biochemical modulation of fluorouracil with leucovorin and Interferon: Preclinical and clinical investigations. Semin Oncol 19(2 Suppl 3):36-44, 1992.
5. Hahn GM: Potential for therapy of drugs and hyperthermia. Cancer Res 39:2264-2268, 1979.
6. Ben-Hur N, Elkind MM: Thermally enhanced radioresponse of cultured Chinese hamster cells: Damage and repair of single-stranded DNA and a DNA complex. Radiat Res 59:484-495, 1974.
7. Louie KG, Behrens BC, Kinsella TJ, et al: Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res 45:2110-2115, 1985.
8. Hamilton TC, Winker MA, Louie KG, et al: Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 34:2583-2586, 1985.
9. O'Dwyer PJ, Hamilton TC, Young RC, et al: Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: Clinical and biochemical results. J Natl Cancer Inst 84:264-267, 1992.
10. Chen G, Zeller WJ: Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and -resistant rat ovarian tumors and its relation to DNA interstrand cross links. Anticancer Res 11:2231-2237, 1991.
11. Lin TS, Prusoff WH: Enhancement of the anticancer activity of bis(2-chloroethyl)nitrosourea in mice by coadministration of 2′-deoxyuridine, 2′-deoxycytidine, or thymidine. Cancer Res 47:394-397, 1987.
12. August EM, Cooper DL, Prusoff WH: Inhibition of poly(adenosine diphosphate-ribose) polymerase by thymidine and thymidine analogues in L1210 cells and its relationship to the potentiation of the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea but not of 3′-[3-(2-chloroethyl)-3-nitrosoureido]-3′-deoxythymidine. Cancer Res 51:1586-1590, 1991.
13. Kufe DW, Beardsley P, Karp D, et al: High-dose thymidine infusions in patients with leukemia and lymphoma. Blood 55:580-589, 1980.
14. Chiuten DF, Wiernik PH, Zaharko DS, et al: Clinical phase I-II and pharmacokinetic study of high-dose thymidine given by continuous intravenous infusion. Cancer Res 40:818-822, 1980.
15. Kufe DW, Wick MM, Moschella S, et al: Effect of high-dose thymidine infusions in patients with mycosis fungoides. Cancer 48:1513-1516, 1981.
16. Leyva A, Schornagel JH, Kraal I, et al: Clinical and biochemical studies of high-dose thymidine treatment in patients with solid tumors. J Cancer Res Clin Oncol 107:211-216, 1984.
17. Blumenreich MS, Woodcock TM, Andreeff M, et al: Effect of very high-dose thymidine infusions on leukemia and lymphoma patients. Cancer Res 44:2203-2207, 1984.
18. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982.
19. Krstulovic AM, Brown AR, Rosie DM: Identification of nucleosides and bases in serum and plasma samples by reverse-phase liquid chromatography. Anal Chem 49:2237-2241, 1977.
20. De Vita VT, Carbone PP, Owens AH Jr, et al: Clinical trials with 1,3,-bis(2-chloroethyl)-1-nitrosourea, NSC-409962. Cancer Res 25:1876-1881, 1965.
21. Schilsky RL, O'Laughlin K, Retain MJ: Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum (II) in patients with advanced cancer. Cancer Res 46:4184-4188, 1986.
22. Vos JM, Hanawalt PC: Processing of psoralen adducts in an active human gene: Repair and replication of DNA containing monoadducts and interstrand cross-links. Cell 50:789-799, 1987.
23. Moertel CG, Reitemeier RJ, Hahn RG: Therapy of advanced gastrointestinal cancer with 1-3-bis-(2-chlorethyl)-1-nitrosourea (BCNU). Clin Pharmacol Ther 9:652-656, 1968.
24. Whittington RM, Fairly JL, Majima H, et al: BCNU (NSC-409962) in the treatment of bronchogenic carcinoma. Cancer Chemother Rep 56:739-743, 1972.
25. Skidmore CJ, Davies MI, Goodwin PM, et al: The involvement of poly(ADP-ribose) polymerase in the degradation of NAD caused by gamma-radiation and N-methyl-N-nitrosourea. Eur J Biochem 101:135-142, 1979.
26. Durkaz BW, Omidiji O, Gray DA, et al: (ADP-ribose)n participates in DNA excision repair. Nature 283:593-596, 1980.
27. n, a new component in DNA repair. In: Chromosome Damage and Repair, edited by E Seeberg, K Kleppe, New York, Plenum Press, 1981, p477.
28. Berger NA: Poly(ADP-ribose) in the cellular response to DNA damage. Radiat Res 101:4-15, 1985.
29. Ben-Hur E, Utsumi H, Elkind MM: Inhibitors of poly (ADP-ribose) synthesis enhance radiation response by differentially affecting repair of potentially lethal versus sublethal damage. Br J Cancer 6(Suppl):39-42, 1984.
30. Chatterjee S, Cheng MF, Berger NA: Hypersensitivity to clinically useful alkylating agents and radiation in poly(ADP-ribose) polymerase-deficient cell lines. Cancer Commun 2:401-407, 1990.
31. Milam KM, Thomas GH, Cleaver JE: Disturbances in DNA precursor metabolism associated with exposure to an inhibitor of poly(ADP-ribose) synthetase. Exp Cell Res 165:260-268, 1986.
32. 2+-dependent endonuclease. Proc Natl Acad Sci USA 72:289-293, 1975.
33. Cleaver JE, Morgan WF: Poly(ADP-ribose)polymerase: A perplexing participant in cellular responses to DNA breakage. Mutat Res 257:1-18, 1991.
34. Satoh MS, Lindahl T: Role of poly(ADP-ribose) formation in DNA repair. Nature 356:356-358, 1992.
35. Carson DA, Seto S, Wasson DB, et al: DNA strand breaks, NAD metabolism, and programmed cell death. Exp Cell Res 164:273-281, 1986.
36. Marks DI, Fox RM: DNA damage, poly (ADP-ribosyl)ation and apoptotic cell death as a potential common pathway of cytotoxic drug action. Biochem Pharmacol 42:1859-1867, 1991.
37. Eastman A, Barry MA: The origin of DNA breaks: A consequence of DNA damage, DNA repair, or apoptosis? Cancer Invest 10:229-240, 1992.
38. Tanizawa A, Kubota M, Hashimoto H, et al: VP-16-induced nucleotide pool changes and poly(ADP-ribose) synthesis: The role of VP-16 in interphase death. Exp Cell Res 185:237-246, 1989.
39. Pivazyan AD, Birks EM, Wood TG, et al: Inhibition of poly(ADP-ribose)polymerase activity by nucleoside analogs of thymidine. Biochem Pharmacol 44:947-953, 1992.